Cytogel Pharma, LLC. Announces the appointment of Alan W. Dunton, M.D. to its Board of Managers
DARIEN, Conn., Sept. 7, 2018
DARIEN, Conn., Sept. 7, 2018 /PRNewswire/ -- C. Dean Maglaris, CEO of Cytogel Pharma, announced today that Alan W. Dunton, M.D. has been named to the Board of Cytogel. Dean stated that "Dr. Dunton brings a depth and breadth of experience and leadership throughout his accomplished career in the pharmaceutical industry and will add significant value to the development of the Company's compounds for moderate to severe pain, starting with CYT-1010. He has worked at the highest level of research and development and has brought many products through full development, including drugs for the treatment of pain."
Dr. Dunton has devoted his 35-year career to the discovery and development of new prescription and OTC drug products. He is a creative and visionary leader who has successfully translated his scientific and clinical/medical knowledge into developing and achieving approval of over 20 commercially successful Rx and OTC drugs. He has led major pharma R&D and Regulatory divisions as well as has been CEO/COO of both public and private biotechnology companies. He was the President and Managing Director of the Janssen Research Foundation – the R&D and Regulatory arm of the pharmaceuticals division at Johnson and Johnson. He has also been at Roche, Syntex, Novartis (as CIBA-GEIGY) and Purdue.
Dr. Dunton holds a M.D. from New York University School of Medicine, where he completed his residency in internal medicine. He was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center. He is a diplomat of the American Board of Internal Medicine and currently licensed to practice medicine in New Jersey and New York. He received his Bachelor of Science degree in biochemistry, magna cum laude, from State University of NY at Buffalo. In 1987, Dr. Dunton was awarded The Nellie Westerman Prize from the American Federation for Clinical Research for his research in medical ethics.
About Cytogel Pharma
Cytogel Pharma, LLC. is a biopharmaceutical development company based in Darien, Connecticut, focused on developing promising early-stage programs that offer significant potential both as platform technologies and high value product candidates for the treatment of pain. Cytogel will develop products to the point of demonstrated value, proof of concept stage, and then license these products to other larger companies for the full scientific and clinical development and subsequent commercialization. To learn more about Cytogel, please visit our website at www.cytogelpharma.com.
Media Contact: C. Dean Maglaris, +1 203 966 9867, firstname.lastname@example.org
SOURCE Cytogel Pharma, LLC.